An interventional study of EUS-guided fine needle aspiration of pancreatic cysts in Pancreatic Cyst and Pancreatitis, Acute, sponsored by Orlando Health, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-31.
Sponsored by Orlando Health, Inc. · Not applicable, Interventional, and Diagnostic
Among 54 studies in Pancreatic Cyst with a site in United States — 20 open to participants now, 23 under way, 1 of them phase 3. Pancreatic Cyst · United States.
Among the 54 studies in Pancreatic Cyst with a site in United States, this one is the 3rd largest by planned enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2022, is one of 13 with no phase, reaches primary completion later than 2 of the 22 other live ones, and was the 43rd registered.
97 studies on the registry are indexed under Pancreatic Cyst; 37 are open to participants now.
Browse Pancreatic Cyst studies →20 of the 54 studies in Pancreatic Cyst with a site in United States are open now. Recruiting first, the newest first:
Orlando Health, Inc. · Sites in United States
Ages 18–100
Translational Genomics Research Institute · Sites in United States
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Orlando Health, Inc. · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 33 Pancreatic Cyst studies recruiting now, 25 (76%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 84 across 38 interventional studies indexed under Pancreatic Cyst.
Median enrollment 53 across the 22 interventional studies, 300 across the 32 observational. Of the 26 that completed or were terminated, 5 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 54 have an industry lead sponsor. The 10 most frequent:
Orlando Health, Inc. is the lead sponsor of 28 studies on the registry; 10 are open to participants now.
Orlando Health, Inc. has 3 studies filed under Pancreatic Cyst — fewer than ten, so there is no comparison to draw.
4 of the studies in Pancreatic Cyst with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05720338Phase 3Case Comprehensive Cancer CenterIs Intraperitoneal Drainage Necessary Following Distal Pancreatectomy? | 2026-12-31 |
| NCT04275557H. Lee Moffitt Cancer Center and Research InstituteUsing Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas | 2026-11 |
| NCT06564571Orlando Health, Inc.Artificial Intelligence in Endoscopic Ultrasound | 2026-12 |
| NCT05692596H. Lee Moffitt Cancer Center and Research InstituteThe Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 54 studies in Pancreatic Cyst with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this randomized trial is to compare the rate of post-procedure pancreatitis in patients undergoing EUS-FNA of pancreatic cysts; patients will receive either a single dose of indomethacin or placebo administered rectally, during EUS-FNA.
Pancreatic cysts are pre-malignant lesions and are being increasingly diagnosed on cross-sectional imaging. Endoscopic ultrasound (EUS) is performed to further evaluate pancreatic cysts, and fine needle aspiration (FNA) is conducted to obtain a sample of the cystic fluid for analysis and examination for malignant cells. Acute pancreatitis is a complication of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) of pancreatic cysts, which can lead to significant morbidity and substantial health care costs. The aim of this randomized trial is to compare the rate of post-procedure pancreatitis in patients undergoing EUS-FNA of pancreatic cysts; patients will receive either a single dose of indomethacin or placebo administered rectally, during EUS-FNA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients assigned to the Indomethacin group will receive100 mg of indomethacin administered per rectal route (two tablets of 50 mg indomethacin suppositories)
Procedure: EUS-guided fine needle aspiration of pancreatic cysts
Patients assigned to the Placebo group will receive two glycerin suppositories.
Procedure: EUS-guided fine needle aspiration of pancreatic cysts
Patients with pancreatic cysts requiring fine needle aspiration will be enrolled in this randomized trial
Rate of post-procedure pancreatitis following EUS-guided fine needle aspiration of pancreatic cysts
Post-procedure pancreatitis is defined as the development of new or increased abdominal pain consistent with acute pancreatitis, and elevated amylase or lipase at least three times the upper limit of normal .
Time frame: 30 days
Rate of procedure-related adverse events
Rate of adverse events resulting from EUS-FNA
Time frame: 30 days
Disease-related adverse events
Any adverse event occurring as a result of underlying pancreatic cyst
Time frame: 30 days
Rate of mild, moderate and severe pancreatitis post-FNA
Rate of mild, moderate and severe pancreatitis post-FNA
Time frame: 30 days
Length of hospitalization in any patient hospitalized with any adverse event
Length of hospitalization in any patient hospitalized with any adverse event
Time frame: 30 days
Length of hospitalization in any patient hospitalized with acute pancreatitis
Length of hospitalization in any patient hospitalized with acute pancreatitis
Time frame: 30 days
Started Sep 2022 (actual). Primary completion is estimated for Jul 2025, 34 months after the start.
Of 17 interventional studies with no phase under Pancreatic Cyst, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 64. This study's planned 34 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Orlando Health, Inc.